Strides Pharma Science posts Q2 net loss of Rs 8.70 cr
- Country:
- India
Drug firm Strides Pharma Science Wednesday reported a consolidated net loss of Rs 8.70 crore for the quarter ended September 30, 2018.
The company had posted a net profit of Rs 11.73 crore for the corresponding period of the previous fiscal, Strides Pharma Science said in a filing to BSE.
Consolidated revenue from operations stood at Rs 732.63 crore for the quarter under consideration. It was Rs 768.66 crore for the same period a year ago.
Commenting on the results, Strides Pharma Science Founder and Group CEO Arun Kumar said, "We have achieved significant progress on our reset strategy both in terms of course-correction and execution over the last two quarters."
With all growth pivots in place, the company is confident of scaling up its diversified B2C business and continue the growth momentum across key markets, he added.
Shares of Strides Pharma Science were trading at Rs 412.85 per scrip on BSE, down 0.22 per cent from their previous close.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
- READ MORE ON:
- Chief Executive
- Science
- Earth science
- Science fair
- Science project
- Political Science
- Data science
- Entrepreneurship
- Entrepreneurship education
- Social entrepreneurship
- Global Entrepreneurship Week
- Entrepreneurship Theory and Practice
- Ministry of Skill Development and Entrepreneurship
- Investment
- State Bank of India
- Finance
- Stock market index
- Stock market
- Moneycontrol.com
- Reliance Retail
ALSO READ
RBI to launch a mobile app to facilitate retail participation in govt securities market: Guv Shaktikanta Das.
Indian rupee has largely remained range-bound among emerging market peers, exhibited lowest volatility in 2023: RBI Guv.
RBI proposes cash deposits through UPI; widens digital currency for retail
RBI to soon launch app to enable retail investors to participate in govt bonds
European Commission examines complaint about Hungary's tax on foreign retailers